Alivus Life Sciences Ltd.

Glenmark Life Sciences has informed that the Company has submitted today March 22, 2024 an application for the reclassification of Glenmark Pharmaceuticals and Glenn Saldanha from ‘promoter and promoter group’ to ‘public shareholders’ to National Stock Exchange of India and BSE for their approval to approve such reclassification.

The above information is a part of company’s filings submitted to BSE.